Trial Outcomes & Findings for Risk of Oxygen During Cardiac Surgery Trial (NCT NCT02361944)
NCT ID: NCT02361944
Last Updated: 2024-02-01
Results Overview
quantified by measuring F2-isoprostanes isofurans following separation from cardiopulmonary bypass or completion of off-pump coronary artery bypass grafting
COMPLETED
PHASE2/PHASE3
213 participants
separation from cardiopulmonary bypass or completion of off-pump coronary artery bypass grafting (approximately 3-5 hours into surgery and intervention)
2024-02-01
Participant Flow
213 patients signed consent. 12 participants were withdrawn prior to randomization. 201 were randomized.
Participant milestones
| Measure |
Normoxia
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
|
Hyperoxia
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
|
|---|---|---|
|
Overall Study
STARTED
|
100
|
101
|
|
Overall Study
COMPLETED
|
100
|
100
|
|
Overall Study
NOT COMPLETED
|
0
|
1
|
Reasons for withdrawal
| Measure |
Normoxia
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
|
Hyperoxia
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
|
|---|---|---|
|
Overall Study
surgery cancellation
|
0
|
1
|
Baseline Characteristics
Risk of Oxygen During Cardiac Surgery Trial
Baseline characteristics by cohort
| Measure |
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
|
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
|
Total
n=200 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
66 years
n=99 Participants
|
64 years
n=107 Participants
|
66 years
n=206 Participants
|
|
Sex: Female, Male
Female
|
26 Participants
n=99 Participants
|
34 Participants
n=107 Participants
|
60 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
74 Participants
n=99 Participants
|
66 Participants
n=107 Participants
|
140 Participants
n=206 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
3 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
4 Participants
n=206 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
97 Participants
n=99 Participants
|
99 Participants
n=107 Participants
|
196 Participants
n=206 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
1 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Black or African American
|
7 Participants
n=99 Participants
|
5 Participants
n=107 Participants
|
12 Participants
n=206 Participants
|
|
Race (NIH/OMB)
White
|
91 Participants
n=99 Participants
|
92 Participants
n=107 Participants
|
183 Participants
n=206 Participants
|
|
Race (NIH/OMB)
More than one race
|
1 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
3 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Region of Enrollment
United States
|
100 participants
n=99 Participants
|
100 participants
n=107 Participants
|
200 participants
n=206 Participants
|
|
Serum Creatinine
|
1.04 mg/dl
n=99 Participants
|
1.08 mg/dl
n=107 Participants
|
1.06 mg/dl
n=206 Participants
|
PRIMARY outcome
Timeframe: separation from cardiopulmonary bypass or completion of off-pump coronary artery bypass grafting (approximately 3-5 hours into surgery and intervention)quantified by measuring F2-isoprostanes isofurans following separation from cardiopulmonary bypass or completion of off-pump coronary artery bypass grafting
Outcome measures
| Measure |
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
|
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
|
|---|---|---|
|
Intraoperative Systemic Oxidative Damage
|
69 pg/ml
Interval 54.0 to 89.0
|
83 pg/ml
Interval 62.0 to 108.0
|
PRIMARY outcome
Timeframe: baseline to postoperative day 2quantified by change in serum creatinine concentration
Outcome measures
| Measure |
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
|
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
|
|---|---|---|
|
Acute Kidney Injury
|
-0.01 mg/dl
Interval -0.16 to 0.19
|
0.01 mg/dl
Interval -0.12 to 0.19
|
SECONDARY outcome
Timeframe: ICU admission (immediately after arrival in ICU from operating room)brachial artery flow mediated dilation assessed when patient arrives in ICU after surgery. brachial artery flow mediated dilation is represented as the percent change in brachial artery diameter following 5 minutes of artery occlusion. The entire assessment takes place at ICU admission.
Outcome measures
| Measure |
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
|
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
|
|---|---|---|
|
Vascular Reactivity / Endothelial Function (as Measured by Flow Mediated Dilation)
|
4.50 percentage change
Interval 1.22 to 8.12
|
4.71 percentage change
Interval 1.8 to 9.68
|
SECONDARY outcome
Timeframe: up to 2 days following surgeryPopulation: Analyzed in subjects with tissue available
mitochondrial function in atrial myocardium estimated by quantifying adenylate kinase at the end of surgery and oxygen intervention
Outcome measures
| Measure |
Normoxia
n=14 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
|
Hyperoxia
n=14 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
|
|---|---|---|
|
Mitochondrial Function
|
1884 Absorbance Units (AU)
Interval 1745.0 to 2236.0
|
1936 Absorbance Units (AU)
Interval 1591.0 to 2078.0
|
SECONDARY outcome
Timeframe: from surgery to hospital discharge, average of 6 days following surgerydefined as any atrial fibrillation following surgery until hospital discharge assessed using continuous telemetry, rhythm strips, and electrocardiograms
Outcome measures
| Measure |
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
|
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
|
|---|---|---|
|
Number of People With Arrhythmia
|
37 Participants
|
46 Participants
|
SECONDARY outcome
Timeframe: morning of postoperative day 1plasma concentration of creatine kinase, myocardial band
Outcome measures
| Measure |
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
|
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
|
|---|---|---|
|
Myocardial Injury or Infarction
|
27.2 ng/ml
Interval 11.5 to 58.3
|
24.5 ng/ml
Interval 13.4 to 40.8
|
SECONDARY outcome
Timeframe: from surgery to hospital discharge, average of 6 days following surgeryDefined as new deficit on neurologic exam and confirmed with radiologic evidence occurring at any point prior to hospital discharge
Outcome measures
| Measure |
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
|
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
|
|---|---|---|
|
Number of People With Stroke
|
1 Participants
|
2 Participants
|
SECONDARY outcome
Timeframe: up to 18 months following surgeryPopulation: Assessed in participants available for long-term follow-up who were able to complete cognitive assessments
Median change scores at the Short Blessed Scale (SBT) administered one-year following surgery. The SBT is a validated rating scale, administered by the clinician, measuring the cognitive performance. Sum Total (range 0-28) with 0 indicating no cognitive impairment and 28 indicating severe cognitive impairment.
Outcome measures
| Measure |
Normoxia
n=57 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
|
Hyperoxia
n=62 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
|
|---|---|---|
|
Postoperative Cognitive Dysfunction
|
3 score on a scale
Interval 0.0 to 6.0
|
2 score on a scale
Interval 0.0 to 4.0
|
SECONDARY outcome
Timeframe: from surgery to hospital discharge, average of 6 days following surgeryreintubation
Outcome measures
| Measure |
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
|
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
|
|---|---|---|
|
Respiratory Failure
|
5 Participants
|
1 Participants
|
SECONDARY outcome
Timeframe: 12 months following surgeryPopulation: eGFR assessed in participants available for long-term follow-up
eGFR one year following surgery
Outcome measures
| Measure |
Normoxia
n=57 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
|
Hyperoxia
n=69 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
|
|---|---|---|
|
Chronic Kidney Disease
|
63.0 ml/min/1.73 meters squared
Interval 50.8 to 84.8
|
60.4 ml/min/1.73 meters squared
Interval 44.3 to 84.4
|
SECONDARY outcome
Timeframe: up to 2 days following surgeryEstimated by quantifying plasma concentration of plasminogen activator inhibitor-1 (PAI-1)
Outcome measures
| Measure |
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
|
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
|
|---|---|---|
|
Inflammation
|
31.08 ng/ml
Interval 25.23 to 40.08
|
36.62 ng/ml
Interval 27.54 to 44.93
|
SECONDARY outcome
Timeframe: separation from cardiopulmonary bypass or completion of off-pump coronary artery bypass grafting (approximately 3-5 hours into surgery and intervention)plasma free hemoglobin
Outcome measures
| Measure |
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
|
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
|
|---|---|---|
|
Hemolysis
|
388,030 ng/ml
|
433,274 ng/ml
|
SECONDARY outcome
Timeframe: end of surgery, defined as immediately after separation from cardiopulmonary bypass or completion of off-pump coronary artery bypass grafting (approximately 3-5 hours into surgery and intervention)TMH electron spin probe
Outcome measures
| Measure |
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
|
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
|
|---|---|---|
|
Reactive Oxygen Species Production
|
165,000 Absorbance Units (AU)
|
180,100 Absorbance Units (AU)
|
SECONDARY outcome
Timeframe: from surgery to hospital discharge, average of 6 days following surgeryThe number of participants with acute brain dysfunction as assessed by the Confusion Assessment Method for the ICU (CAM-ICU) twice daily while patients are in the ICU or for first 3 postoperative days.
Outcome measures
| Measure |
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
|
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
|
|---|---|---|
|
Acute Brain Dysfunction (Delirium)
|
16 Participants
|
22 Participants
|
SECONDARY outcome
Timeframe: ICU admission (immediately after arrival in ICU from operating room)arterial lactate measured from arterial blood collected at ICU admission (immediately after arrival in ICU from operating room)
Outcome measures
| Measure |
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
|
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
|
|---|---|---|
|
Oxygenation and Perfusion (Lactate)
|
1.5 mmol/liter
Interval 1.2 to 2.3
|
1.8 mmol/liter
Interval 1.3 to 2.9
|
SECONDARY outcome
Timeframe: up to 7 days following surgeryKDIGO acute kidney injury is defined as an increase in SCr ≥ 0.3 mg/dL (≥ 26.5 lmol/L) within 48 hours of surgery or 1.5 to 1.9 times baseline within 7 days of surgery
Outcome measures
| Measure |
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
|
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
|
|---|---|---|
|
Acute Kidney Injury, According to KDIGO Criteria
|
21 Participants
|
21 Participants
|
SECONDARY outcome
Timeframe: baseline to 2 days following surgeryUrinary concentration of \[TIMP2\]\*\[IGFBP7\] 6 hours after ICU admission
Outcome measures
| Measure |
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
|
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
|
|---|---|---|
|
Acute Kidney Injury Estimated by Urine Concentration of TIMP-2 IGFBP7
|
0.224 (ng/ml) squared
Interval 0.112 to 0.486
|
0.187 (ng/ml) squared
Interval 0.075 to 0.423
|
SECONDARY outcome
Timeframe: baseline to 2 days following surgeryUrinary concentration of neutrophil gelatinase-associated lipocalin (NGAL) 6 hours after ICU admission.
Outcome measures
| Measure |
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
|
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
|
|---|---|---|
|
Acute Kidney Injury Estimated by Urine Concentration of NGAL
|
6.9 ng/ml
Interval 3.0 to 17.5
|
4.8 ng/ml
Interval 2.9 to 14.1
|
SECONDARY outcome
Timeframe: end of surgery, defined as immediately after separation from cardiopulmonary bypass or completion of off-pump coronary artery bypass grafting (approximately 3-5 hours into surgery and intervention)CAT1H electron spin probe
Outcome measures
| Measure |
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
|
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
|
|---|---|---|
|
Reactive Oxygen Species Production
|
17,300 Absorbance Units (AU)
Interval 8138.0 to
|
17,040 Absorbance Units (AU)
Interval 9788.0 to
|
SECONDARY outcome
Timeframe: during surgeryhemoglobin O2 saturation summarized using SpO2 data continuously measured and recorded every minute during surgery. We calculated the median SpO2 throughout surgery using all the minute to minute values. For example, if a participant had a 5 hour (300 minutes) long surgery, the participant would have 300 SpO2 measurements. We calculated and report the median of those measurements.
Outcome measures
| Measure |
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
|
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
|
|---|---|---|
|
Oxygenation and Perfusion (SpO2)
|
97 percent saturation
Interval 97.0 to 98.0
|
100 percent saturation
Interval 100.0 to 100.0
|
SECONDARY outcome
Timeframe: end of surgery, defined as separation from cardiopulmonary bypass or completion of off-pump coronary artery bypass grafting (approximately 3-5 hours into surgery and intervention)partial pressure of oxygen in arterial blood measured from blood sampled at end of surgery, defined as following separation from cardiopulmonary bypass or completion of off-pump coronary artery bypass grafting (approximately 3-5 hours into surgery and intervention)
Outcome measures
| Measure |
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
|
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
|
|---|---|---|
|
Oxygenation and Perfusion (PaO2)
|
99 mmHg
Interval 96.0 to 105.0
|
377 mmHg
Interval 332.0 to 426.0
|
SECONDARY outcome
Timeframe: continuously assessed throughout surgery and recorded each minutebrain hemoglobin oxygenation using near-infrared spectroscopy (NIRS). The median percent changes from baseline (baseline measured at beginning of surgery when probes placed on forehead, prior to intervention) throughout surgery was calculated using cerebral oximetry measurements collected every minute throughout surgery. We calculated the difference between baseline and each measurement throughout surgery. For example, if a participant had a 5 hour (300 minutes) long surgery, the participant would have 300 cerebral oximetry measurements. We calculated and report the median of those measurements.
Outcome measures
| Measure |
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
|
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
|
|---|---|---|
|
Oxygenation and Perfusion (Cerebral Oximetry)
|
-7.2 percentage change from baseline
Interval -14.4 to -0.2
|
6.0 percentage change from baseline
Interval 0.0 to 14.4
|
SECONDARY outcome
Timeframe: end of surgery, defined as following separation from cardiopulmonary bypass or completion of off-pump coronary artery bypass grafting (approximately 3-5 hours into surgery and intervention)mixed venous O2 saturation, measured from blood sampled from pulmonary artery sampled at end of surgery, defined as following separation from cardiopulmonary bypass or completion of off-pump coronary artery bypass grafting (approximately 3-5 hours into surgery and intervention)
Outcome measures
| Measure |
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
|
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
|
|---|---|---|
|
Oxygenation and Perfusion (SvO2)
|
68 percent saturation
Interval 65.0 to 73.0
|
78 percent saturation
Interval 71.0 to 83.0
|
SECONDARY outcome
Timeframe: end of surgery, defined as immediately after separation from cardiopulmonary bypass or completion of off-pump coronary artery bypass grafting (approximately 3-5 hours into surgery and intervention)cardiac output (normalized to body surface area, i.e., cardiac index)
Outcome measures
| Measure |
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
|
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
|
|---|---|---|
|
Oxygenation and Perfusion (Cardiac Index)
|
2.56 liters/min/meter squared
Interval 2.14 to 2.88
|
2.48 liters/min/meter squared
Interval 1.96 to 3.14
|
SECONDARY outcome
Timeframe: ICU admission (immediately after arrival in ICU from operating room)reactive hyperemia index measured at ICU admission (immediately after arrival in ICU from operating room). The reactive hyperemia index is a number generated by an endopat machine performing peripheral artery tonometry. The index ranges from approximately 1-3, where higher values indicate better vascular reactivity and endothelial function.
Outcome measures
| Measure |
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
|
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
|
|---|---|---|
|
Vascular Reactivity / Endothelial Function (Peripheral Artery Tonometry)
|
1.41 index
Interval 1.14 to 1.78
|
1.23 index
Interval 0.91 to 1.65
|
SECONDARY outcome
Timeframe: tissue collected during surgery when heart is exposed approximately 2 hours into interventionEffective concentration for 50% dilation acetylcholine dose response, tension wire myography from arterioles dissected from epicardial fat
Outcome measures
| Measure |
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
|
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
|
|---|---|---|
|
Vascular Reactivity / Endothelial Function (Tension Wire Myography, Endothelial Dependent Vasodilation, EC50)
|
-6.13 log Molar
Interval -6.57 to -5.7
|
-5.92 log Molar
Interval -6.36 to -5.48
|
SECONDARY outcome
Timeframe: tissue collected during surgery when heart is exposed approximately 2 hours into interventionMaximum percentage of arteriole dilation after increasing doses of acetylcholine measured using tension wire myography of arterioles dissected from epicardial fat. The fat sample was collected during surgery when heart is exposed approximately 2 hours into intervention.
Outcome measures
| Measure |
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
|
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
|
|---|---|---|
|
Vascular Reactivity / Endothelial Function (Tension Wire Myography, Endothelial Dependent Vasodilation, Emax)
|
36.2 percent relaxation
Interval 25.5 to 46.9
|
39.5 percent relaxation
Interval 24.5 to 51.5
|
SECONDARY outcome
Timeframe: tissue collected during surgery when heart is exposed approximately 2 hours into interventionEffective concentration for 50% dilation sodium nitroprusside dose response, tension wire myography from arterioles dissected from epicardial fat
Outcome measures
| Measure |
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
|
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
|
|---|---|---|
|
Vascular Reactivity / Endothelial Function (Tension Wire Myography, Endothelial Independent Vasodilation, EC50)
|
-6.95 log Molar
Interval -7.37 to -6.53
|
-5.75 log Molar
Interval -6.21 to -5.29
|
SECONDARY outcome
Timeframe: tissue collected during surgery when heart is exposed approximately 2 hours into interventionMaximum percentage of arteriole dilation after increasing doses of sodium nitroprusside measured using tension wire myography of arterioles dissected from epicardial fat. The fat sample was collected during surgery when heart is exposed approximately 2 hours into intervention.
Outcome measures
| Measure |
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
|
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
|
|---|---|---|
|
Vascular Reactivity / Endothelial Function (Tension Wire Myography, Endothelial Independent Vasodilation, Emax)
|
91.5 percent relaxation
Interval 83.8 to 99.2
|
92.6 percent relaxation
Interval 82.8 to 102.4
|
SECONDARY outcome
Timeframe: tissue collected during surgery when heart is exposed approximately 2 hours into interventionEffective concentration for 50% dilation cinaciguat dose response, tension wire myography from arterioles dissected from epicardial fat
Outcome measures
| Measure |
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
|
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
|
|---|---|---|
|
Vascular Reactivity / Endothelial Function (Tension Wire Myography, sGC Activation Vasodilation, EC50)
|
-6.89 log Molar
Interval -7.48 to -6.3
|
-6.66 log Molar
Interval -7.2 to -6.12
|
SECONDARY outcome
Timeframe: tissue collected during surgery when heart is exposed approximately 2 hours into interventionMaximum percentage of arteriole dilation after increasing doses of cinaciguat measured using tension wire myography of arterioles dissected from epicardial fat. The fat sample was collected during surgery when heart is exposed approximately 2 hours into intervention.
Outcome measures
| Measure |
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
|
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
|
|---|---|---|
|
Vascular Reactivity / Endothelial Function (Tension Wire Myography, sGC Activation Vasodilation, Emax)
|
97.1 percent relaxation
Interval 92.9 to 101.4
|
96.0 percent relaxation
Interval 91.9 to 100.2
|
SECONDARY outcome
Timeframe: end of surgery, defined as immediately after separation from cardiopulmonary bypass or completion of off-pump coronary artery bypass grafting (approximately 3-5 hours into surgery and intervention)Plasminogen activator inhibitor 1
Outcome measures
| Measure |
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
|
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
|
|---|---|---|
|
Vascular Reactivity / Endothelial Function (PAI-1)
|
31.2 ng/ml
Interval 25.2 to 40.1
|
36.6 ng/ml
Interval 27.5 to 44.9
|
SECONDARY outcome
Timeframe: end of surgery, defined as immediately after separation from cardiopulmonary bypass or completion of off-pump coronary artery bypass grafting (approximately 3-5 hours into surgery and intervention)E-selectin
Outcome measures
| Measure |
Normoxia
n=100 Participants
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
|
Hyperoxia
n=100 Participants
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
|
|---|---|---|
|
Vascular Reactivity / Endothelial Function (E-selectin)
|
16.4 ng/ml
Interval 11.0 to 19.7
|
16.2 ng/ml
Interval 11.3 to 25.0
|
Adverse Events
Normoxia
Hyperoxia
Serious adverse events
| Measure |
Normoxia
n=100 participants at risk
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
|
Hyperoxia
n=100 participants at risk
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
|
|---|---|---|
|
Cardiac disorders
Category: Arrythmia, Pacemaker or Cardiac Arrest
|
3.0%
3/100 • Number of events 3 • baseline to one year following surgery
|
5.0%
5/100 • Number of events 5 • baseline to one year following surgery
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
0.00%
0/100 • baseline to one year following surgery
|
1.0%
1/100 • Number of events 1 • baseline to one year following surgery
|
|
Cardiac disorders
right ventricular failure
|
0.00%
0/100 • baseline to one year following surgery
|
1.0%
1/100 • Number of events 1 • baseline to one year following surgery
|
|
Blood and lymphatic system disorders
heparin-induced thrombocytopenia
|
0.00%
0/100 • baseline to one year following surgery
|
1.0%
1/100 • Number of events 1 • baseline to one year following surgery
|
|
Immune system disorders
anaphylaxis
|
0.00%
0/100 • baseline to one year following surgery
|
1.0%
1/100 • Number of events 1 • baseline to one year following surgery
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.00%
0/100 • baseline to one year following surgery
|
1.0%
1/100 • Number of events 1 • baseline to one year following surgery
|
|
Nervous system disorders
Seizure
|
2.0%
2/100 • Number of events 2 • baseline to one year following surgery
|
1.0%
1/100 • Number of events 1 • baseline to one year following surgery
|
|
Surgical and medical procedures
Surgical complications requiring valve replacement revision
|
2.0%
2/100 • Number of events 2 • baseline to one year following surgery
|
0.00%
0/100 • baseline to one year following surgery
|
|
Psychiatric disorders
Severe postoperative hallucinations
|
1.0%
1/100 • Number of events 1 • baseline to one year following surgery
|
0.00%
0/100 • baseline to one year following surgery
|
Other adverse events
| Measure |
Normoxia
n=100 participants at risk
Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
Oxygen - normoxia: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
|
Hyperoxia
n=100 participants at risk
Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
Oxygen - hyperoxia: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
|
|---|---|---|
|
Immune system disorders
Fever
|
9.0%
9/100 • Number of events 9 • baseline to one year following surgery
|
6.0%
6/100 • Number of events 6 • baseline to one year following surgery
|
|
Cardiac disorders
Tachycardia
|
5.0%
5/100 • Number of events 5 • baseline to one year following surgery
|
8.0%
8/100 • Number of events 8 • baseline to one year following surgery
|
|
Vascular disorders
Hypotension
|
29.0%
29/100 • Number of events 29 • baseline to one year following surgery
|
25.0%
25/100 • Number of events 25 • baseline to one year following surgery
|
|
Vascular disorders
Vasoplegia
|
34.0%
34/100 • Number of events 34 • baseline to one year following surgery
|
28.0%
28/100 • Number of events 28 • baseline to one year following surgery
|
|
Cardiac disorders
Decreased cardiac output
|
2.0%
2/100 • Number of events 2 • baseline to one year following surgery
|
5.0%
5/100 • Number of events 5 • baseline to one year following surgery
|
|
Blood and lymphatic system disorders
Anemia
|
49.0%
49/100 • Number of events 49 • baseline to one year following surgery
|
48.0%
48/100 • Number of events 48 • baseline to one year following surgery
|
|
Blood and lymphatic system disorders
Leukocytosis
|
37.0%
37/100 • Number of events 37 • baseline to one year following surgery
|
47.0%
47/100 • Number of events 47 • baseline to one year following surgery
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
1.0%
1/100 • Number of events 1 • baseline to one year following surgery
|
1.0%
1/100 • Number of events 1 • baseline to one year following surgery
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place